Crossmark

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD

Crossref DOI link: https://doi.org/10.1136/rmdopen-2021-001896

Published Online: 2021-10-20

Published Print: 2021-10

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Regierer, Anne Constanze https://orcid.org/0000-0003-2456-4049
Hasseli, Rebecca https://orcid.org/0000-0002-2982-8253
Schäfer, Martin https://orcid.org/0000-0001-6487-3634
Hoyer, Bimba F https://orcid.org/0000-0002-5252-1719
Krause, Andreas

Lorenz, Hanns-Martin

Pfeil, Alexander https://orcid.org/0000-0002-2709-6685
Richter, Jutta

Schmeiser, Tim

Schulze-Koops, Hendrik https://orcid.org/0000-0002-1681-491X
Strangfeld, Anja https://orcid.org/0000-0002-6233-022X
Voll, Reinhard E

Specker, Christof https://orcid.org/0000-0003-2504-3229
Mueller-Ladner, Ulf
Funding

Funding for this research was provided by:

Justus-Liebig-University Giessen
License Information

License valid from 2021-10-19